GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cereno Scientific AB (OSTO:CRNO B) » Definitions » EBITDA Margin %

Cereno Scientific AB (OSTO:CRNO B) EBITDA Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cereno Scientific AB EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cereno Scientific AB's EBITDA for the three months ended in Sep. 2024 was kr-15.19 Mil. Cereno Scientific AB's Revenue for the three months ended in Sep. 2024 was kr0.00 Mil. Therefore, Cereno Scientific AB's EBITDA margin for the quarter that ended in Sep. 2024 was 0.00%.


Cereno Scientific AB EBITDA Margin % Historical Data

The historical data trend for Cereno Scientific AB's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cereno Scientific AB EBITDA Margin % Chart

Cereno Scientific AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only - - - - -

Cereno Scientific AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cereno Scientific AB's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Cereno Scientific AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cereno Scientific AB's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cereno Scientific AB's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Cereno Scientific AB's EBITDA Margin % falls into.



Cereno Scientific AB EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Cereno Scientific AB's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-42.795/0
= %

Cereno Scientific AB's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-15.19/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cereno Scientific AB  (OSTO:CRNO B) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Cereno Scientific AB EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Cereno Scientific AB's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cereno Scientific AB Business Description

Traded in Other Exchanges
Address
BioVentureHub, Pepparedsleden 1, Molndal, SWE, 431 83
Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientificalso evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.

Cereno Scientific AB Headlines

No Headlines